Intensity Therapeutics, Inc.
INTS
$1.85
-$0.01-0.54%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 72.40% | 149.77% | 201.36% | 124.94% | 46.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 99.39% | 159.85% | 173.85% | 83.75% | 10.17% |
| Operating Income | -99.39% | -159.85% | -173.85% | -83.75% | -10.17% |
| Income Before Tax | -54.37% | -83.17% | -81.14% | -110.80% | -38.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.37% | -83.17% | -81.14% | -110.80% | -38.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.37% | -83.17% | -81.14% | -110.80% | -38.99% |
| EBIT | -99.39% | -159.85% | -173.85% | -83.75% | -10.17% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 47.17% | 51.39% | 60.52% | -12.76% | 0.08% |
| Normalized Basic EPS | 2.37% | 16.37% | 37.70% | 40.33% | 45.93% |
| EPS Diluted | 37.22% | 51.39% | 60.52% | -12.76% | 0.08% |
| Normalized Diluted EPS | 2.37% | 16.37% | 37.70% | 40.33% | 45.93% |
| Average Basic Shares Outstanding | 61.93% | 129.16% | 298.98% | 227.35% | 151.84% |
| Average Diluted Shares Outstanding | 61.93% | 129.16% | 298.98% | 227.35% | 151.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |